# US 10,870,685 B2 · Immunotherapy with A*01 restricted peptides and combination of peptides against cancers and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,685 B2
- Document ID: US10870685B2
- Status: Granted
- Kind: B2
- Application number: 16/917,040
- Filed: 2020-06-30
- Published: 2020-10-15
- Granted: 2020-12-22
- Earliest claimed: 2018-09-18
- Assignees: Immatics Biotechnologies GmbH
- Applicants: Immatics Biotechnologies GmbH
- Inventors: Heiko Schuster; Annika Sonntag; Daniel Johannes Kowalewski; Oliver Schoor; Jens Fritsche; Toni Weinschenk; Harpreet Singh; Colette Song
- Web page: https://patentgrep.com/patent/US10870685B2

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/0011: {Cancer antigens}
- A61K 2039/572: {cytotoxic response}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

## Claims

### Claim 1

A method of treating a patient who has cancer overexpressing ZNF215 polypeptide comprising the amino acid sequence of SEQ ID NO: 78, comprising administering to said patient a population of activated T cells that kill the cancer cells,
wherein the activated T cells are cytotoxic T cells produced by contacting CD8+ T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 78 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from breast cancer, colorectal cancer, gallbladder cancer, gastric cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer adenocarcinoma, squamous cell non-small cell lung cancer, esophageal cancer, pancreatic cancer, small cell lung cancer, urinary bladder carcinoma, and uterine and endometrial cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the T cells are autologous to the patient.

### Claim 3 (depends on 1)

The method of claim 1, wherein the T cells are obtained from a healthy donor.

### Claim 4 (depends on 1)

The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

### Claim 6 (depends on 1)

The method of claim 1, wherein the MEW class I molecule is HLA-A*01.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is colorectal cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is gallbladder cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is gastric cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is hepatocellular carcinoma.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is head and neck squamous cell carcinoma.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is melanoma.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is non-Hodgkin lymphoma.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung cancer adenocarcinoma or squamous cell non-small cell lung cancer.

### Claim 16 (depends on 1)

The method of claim 1, wherein the cancer is esophageal cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic cancer.

### Claim 18 (depends on 1)

The method of claim 1, wherein the cancer is small cell lung cancer.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cancer is urinary bladder carcinoma.

### Claim 20 (depends on 1)

The method of claim 1, wherein the cancer is uterine and endometrial cancer.